Investigations › GLP-1 era
Investigation No. 07 · GLP-1 era
“Once you stop GLP-1 you regain everything”
Weight does return for most people. That finding is about pharmacology and it is usually deployed to answer a question about your life.
At a glance
- Verdict
- Partly true
- Certainty in the evidence
- Moderate, starting at High and moved by 1 domain
- Evidence base
- STEP 4 withdrawal trial (n=803) and STEP 1 extension (n=327) · 2 studies read · 1,130 people
- Last reviewed
- 11 Sept 2026
- Next review due
- Mar 2027
How people actually say it
- “What’s the point, you just put it all back on.”almost always said as a reason not to start
- “My cousin lost sixty pounds and gained it all back.”one person, used to settle a decision
Why this verdict and not the next one
Partly true rather than mostly false, because the regain is real and well measured. What the claim omits is the condition: it was measured in people who lost their support on the same day as the drug.
Where the claim came from
From a real trial extension, reported accurately, then put to work on a question it was not built for. Does the effect persist after stopping is a question about a drug. Is this worth doing is a question about your risk and what else is on offer.
What the studies did
The STEP 1 extension followed 327 participants for 52 weeks after both the drug and the support ended: about 17 percent lost by week 68, roughly two thirds regained. STEP 4 is the better comparison and gets quoted far less. Everybody kept the lifestyle support, and those randomized to continue lost a further 7.9 percent while those switched to placebo regained about 6.9 percent.
Why these papers and not others
Two trials, chosen because they differ in the one way that matters: STEP 4 kept the lifestyle support and the STEP 1 extension did not. Single-arm follow-ups and registry reports were left out, since neither can say what would have happened anyway.
The full search and appraisal protocol, including what gets excluded and why, is set out in the method.
The evidence, study by study
| Study | Design | n | What it found | What it cannot say |
|---|---|---|---|---|
| Rubino 2021, STEP 4 | Randomized withdrawal, lifestyle support kept in both arms | 803 | Continuing lost a further 7.9 percent. Switching to placebo regained about 6.9 percent | Whether what somebody built during treatment changes the curve |
| Wilding 2022, STEP 1 extension | Observational follow-up after drug and program both stopped | 327 | About two thirds of the lost weight returned over 52 weeks, and cardiometabolic markers drifted back | What stopping the drug alone would have done |
How the certainty grade was reached
Certainty starts at a level set by the study design, then moves down for every domain that fails a written threshold and up for every domain that clears one. The arithmetic is shown rather than asserted.
What the evidence cannot say
Neither trial tested what happens to somebody who used the treated year to build strength, an eating pattern and a sleep schedule. That study does not exist in a form that answers the question, in either direction.
One person, worked through
She is 52, BMI 34, told by a cardiologist to lose weight, four serious attempts in fifteen years. She is using the regain finding to decide against starting. The regain data describes people who lost all support on one day. The outcome data describes people closer to her. Neither tells her what to do, and both change which question she is actually answering.
Whether this applies to you
A verdict is a reading of a population. Whether it describes you depends on the things below, and any one of them can change what the right move is for you.
- Why you would be stopping changes everything. Cost, side effects, pregnancy and choice are four situations
- What you build while on it is unmeasured and is the only part you control
- Your risk untreated is the comparison this turns on, and almost nobody is offered it
What would change this entry
A randomized trial that keeps lifestyle support in place, stops the drug in one arm, and separates people by what they built during treatment.
Read this before you act on it
This is an appraisal of published evidence, not medical or nutrition advice, and it is not a substitute for care from a clinician who knows your history, your medications and your labs. Nothing here is a diagnosis, a prescription or a treatment plan, and reading it does not create a clinician and patient relationship.
Do not start, stop or change a medication, a supplement or a diet on the strength of this page. If you are pregnant, breastfeeding, managing kidney or liver disease, diabetes, an eating disorder or any chronic condition, the general reading above may not describe you at all. Talk to your physician or a registered dietitian first.
The verdict above was true to the evidence on 11 Sept 2026. Evidence moves. Check the review date.
References
- Wilding JPH et al. Diabetes Obes Metab. 2022;24(8):1553–1564. PMID 35441470. · Rubino D et al. JAMA. 2021;325(14):1414–1425. PMID 33755728.
